Pharmacotherapy for Tourette Syndrome

Area of Science:

• Neuroscience
• Pharmacology
• Neurology

Background:

• Tourette syndrome (TS) is characterized by dysregulated cortico-striatal-thalamo-cortical neural circuits.
• Key neurotransmitters implicated in TS include dopamine, glutamate, and gamma-aminobutyric acid.
• Pharmacologic intervention is considered for tics causing significant impairment when behavioral treatments are ineffective or unavailable.

Purpose of the Study:

• To review current pharmacologic interventions for Tourette syndrome.
• To discuss FDA-approved and off-label medication options.
• To outline common treatment approaches and emerging therapies.

Main Methods:

• Literature review of pharmacological treatments for Tourette syndrome.
• Analysis of FDA-approved medications for TS.
• Discussion of common first-line and alternative pharmacologic strategies.

Main Results:

• Only three medications (pimozide, haloperidol, aripiprazole) are FDA-approved for TS.
• Off-label pharmacologic interventions are frequently utilized.
• Common treatment sequences involve alpha-agonists, atypical antipsychotics, then typical antipsychotics.

Conclusions:

• Current pharmacologic treatment for TS relies on a limited number of approved medications.
• Off-label use and sequential treatment strategies are common.
• Novel pharmacological approaches with new mechanisms of action are under development for TS.